174 related articles for article (PubMed ID: 7905197)
1. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
Gagnon C; Gomez-Mancilla B; Bédard PJ; Di Paolo T
Neurosci Lett; 1993 Nov; 163(1):31-5. PubMed ID: 7905197
[TBL] [Abstract][Full Text] [Related]
2. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
Gagnon C; Gomez-Mancilla B; Markstein R; Bédard PJ; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):667-76. PubMed ID: 8588064
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Graham WC; Sambrook MA; Crossman AR
Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
[TBL] [Abstract][Full Text] [Related]
5. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
6. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Calon F; Goulet M; Blanchet PJ; Martel JC; Piercey MF; Bédard PJ; Di Paolo T
Brain Res; 1995 May; 680(1-2):43-52. PubMed ID: 7663983
[TBL] [Abstract][Full Text] [Related]
7. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
8. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content.
Calon F; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Neurochem Int; 1999 Jul; 35(1):81-91. PubMed ID: 10403433
[TBL] [Abstract][Full Text] [Related]
9. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
[TBL] [Abstract][Full Text] [Related]
10. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
11. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
Luquin MR; Guillén J; Martínez-Vila E; Laguna J; Martínez-Lage JM
Eur J Pharmacol; 1994 Mar; 253(3):215-24. PubMed ID: 7911084
[TBL] [Abstract][Full Text] [Related]
12. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
Nomoto M; Fukuda T
Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
[No Abstract] [Full Text] [Related]
13. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
[TBL] [Abstract][Full Text] [Related]
14. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
Gomez-Mancilla B; Bédard PJ
Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
[TBL] [Abstract][Full Text] [Related]
15. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
Alexander GM; Schwartzman RJ; Grothusen JR; Brainard L; Gordon SW
Brain Res; 1993 Oct; 625(2):276-82. PubMed ID: 8275309
[TBL] [Abstract][Full Text] [Related]
16. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.
Calon F; Morissette M; Ghribi O; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):127-38. PubMed ID: 11853103
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958.
Grondin R; Goulet M; Morissette M; Bédard PJ; Di Paolo T
Eur J Pharmacol; 1999 Aug; 378(3):259-63. PubMed ID: 10493101
[TBL] [Abstract][Full Text] [Related]
18. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Rouillard C; Bédard PJ; Di Paolo T
Eur J Pharmacol; 1990 Aug; 185(2-3):209-15. PubMed ID: 2253695
[TBL] [Abstract][Full Text] [Related]
19. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
20. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
